Karyopharm's Xpovio (selinexor) Competetive positioning in DLBC

NEW YORK - Aug. 11, 2020 - PRLog -- Karyopharm's Selinexor (Xpovio)  an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma. The drug is also approved a year ago as the "last line" treatment option for relapsed/refractory Multiple Myeloma patients.

Key Takeaways by Mellalta Meets

Selinexor (Xpovio) Marketing Positioning Statements

First oral therapy approved for RR DLBCL

First single agent approved in any line of DLBCL treatment

First therapy a RR DLBCL patient can take at home

Selinexor (Xpovio) Market Positioning

Selinexor (Xpovio) will be preferred as a DLBCL treatment option after two prior lines of therapy

An Estimated 9,000 DLBCL Patients Being Treated in the 3rd and 4th Line+ Setting in the U.S.

Recent FDA approvals of CAR-T therapy (2017 and 2019) and polatuzumab + bendamustine + rituximab (2019)

The approval of Karyopharm's Xpovio (selinexor) in patients with relapsed or refractory DLBCL is a huge milestone for the patients and families suffering as they have limited treatment options available for their disease.

Submit your Request for Proposals at bd@mellalta.com

https://mellalta.com/how-selinexor-xpovio-is-positioned-in-competitive-r-r-dlbcl-market/